ClinicalTrials.gg
CompletedNCT02515305Updated Nov 8, 2021Results posted

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris

A Phase 3 interventional study of Clindamycin and Benzoyl Peroxide Gel (combination) and Clindamycin and Benzoyl Peroxide Gel (Reference) (combination) in Acne, sponsored by Padagis LLC. Completed at 1 site in United States. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-11-08.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
890
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.

Enrollment
7th of 34
890 · median 117
Started
2015
with 4 others
Phase 3
9 of 34
none open now
Registered
28th of 34
by date
Lead sponsor
2 of 34
Padagis LLC

Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 7th largest by enrollment, is one of 5 that started in 2015, is one of 9 in phase 3, and was the 28th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About clindamycin

Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing clindamycin in Acne Vulgaris, or all of them as a file.
02

Study summary

The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris

03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written /assent
  2. Healthy male or non-pregnant females, 12 to 40 years of age, inclusive
  3. Definite clinical diagnosis of acne vulgaris with an inflammatory lesion (papules and pustules) count between 20 and 50 and a non-inflammatory (open and closed comedones) lesion count between 25 and 100 and no more than 2 nodulocystic lesions (i.e., nodules and cysts) including those present on the nose.
  4. Baseline IGA score of 3 or 4 on a scale of 0 to 4.
  5. Willing and able to understand and comply with the requirements of the study, apply the medication as instructed, refrain from use of all other topical acne medication or topical antibiotics during the 12-week treatment period, return for the required treatment period visits, comply with therapy prohibitions, and are able to complete the study.
  6. Be in general good health and free from any disease, other than acne vulgaris, that might interfere with the study evaluations.
  7. Females of willing to use an acceptable form of

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, nursing, or planning a pregnancy within the study participation period
  2. More than 2 facial nodulocystic lesions (i.e. nodules and cysts).
  3. Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.).
  4. Active cystic acne or Polycystic Ovarian Syndrome.
  5. History or presence of Crohn's disease, ulcerative colitis, regional enteritis, inflammatory bowel disease, pseudomembranous colitis, chronic or recurrent diarrhea or antibiotic-associated colitis.
  6. Use of neuromuscular blocking agents (nondepolarizing agents and depolarizing agents) Subjects who have had general anesthesia for any reason and subjects who have received neuromuscular blocking agents within 14 days prior to study entry will be excluded from study participation.
  7. Presence of any other facial skin condition that might interfere with acne vulgaris diagnosis and/or assessment (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, acne, steroid folliculitis, sunburn or bacterial folliculitis).
  8. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
  9. History of unresponsiveness to topical Clindamycin Phosphate and/or benzoyl peroxide therapy.
  10. Use of systemic Clindamycin products 4 weeks (30 days) prior to baseline or throughout the study.
  11. History of or allergy to Clindamycin Phosphate, benzoyl peroxide and/or any ingredient in the study medication.
  12. Use within 6 months (180 days) prior to baseline or during the study of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  13. Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit 1/Day 1 (Baseline).
  14. Use within 30 days (1 month) prior to baseline or during the study of therapeutic vitamin D supplement (daily multivitamins with total 800IU Vitamin D are allowed).
  15. Use of medications known to exacerbate acne (Vitamin B12, lithium, corticosteroids; Vitamin B12, etc. as part of a multivitamin regimen is allowed).
  16. Start or change of dose of hormonal treatment (oral, implanted, topical and androgens) 3 months (90 days) prior to baseline or throughout the study. Use of such therapy must remain constant during the study.
  17. Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days (1 month) of study entry and throughout the study (other than study supplied cleanser and lotion).
  18. Use within 30 days (1 month) prior to baseline or during the study of 1) spironolactone, 2) systemic steroids*, 3) systemic (e.g., oral or injectable) antibiotics, 4) systemic treatment for acne vulgaris (other than oral retinoids which require a 6-month washout), or 5) agents**. (*Intranasal and inhaled corticosteroids do not require a and may be used throughout the study if at a stable and standard dose.)** Subjects may use systemic anti-inflammatory agents (i.e., NSAIDs (Ibuprofen or Aspirin) for pain relief) as needed (with no more than 7 days of consecutive use) throughout the study. Prophylactic use of low dose Aspirin 81 mg is allowed. *** Subjects may use Acetaminophen for pain relief, as needed throughout the study
  19. Use within 14 days (2 weeks) prior to baseline or during the study of 1) topical steroids, 2) topical retinoids, 3) topical anti-acne medications (e.g. Benzoyl peroxide, retinoids, azelaic acid, α-hydroxy/glycolic acid, Clindamycin, etc.) including OTC preparations 4) topical anti-inflammatory agents, or 5) topical antibiotics.
  20. Use on the face within 1 month (30 days) prior to baseline or during the study of 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
  21. Use of medicated cleansers (e.g. benzoyl peroxide, salicylic acid, sulfur or triclosan) within 2 weeks (14 days) of study start and throughout the study.
  22. Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
  23. Use of Antipruritics, including antihistamines within 24 hours (1day) of all study visits (Visit 1 through Visit 4).
  24. Participation in any clinical study involving an product, agent or device ( that might influence the intended effects or mask the side effects of study medication ) in the 4 weeks (30 days) prior Visit 1/Day 1 (Baseline) or throughout the study.
  25. Previous enrollment in this study or current enrollment in this study at another participating site.
  26. Employee (or employee's family member) of the research center or private practice, or subjects who have a conflict of interest.
  27. Use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun 1 week (7 days) prior to enrollment and throughout the study.
  28. Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
890 participants (actual)

Study arms

  • Experimental
    Test product

    Drug: Clindamycin and Benzoyl Peroxide Gel (combination)

  • Active comparator
    Reference product

    Drug: Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)

  • Placebo comparator
    Placebo product

    Drug: Placebo gel (combination)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions

    Time frame: Baseline to Day 84

  2. Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions

    Time frame: Baseline to Day 84

07

Results

Posted Nov 16, 2020

Participant flow

Participant flow — Overall Study
MilestoneTest ProductReference ProductPlacebo Product
Started385378127
Completed356343113
Not completed293514

Outcome measures

PrimaryMean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions
Time frame:
Baseline to Day 84
Reported as:
Mean · percentage of lesion change
Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions
percentage of lesion changeTest ProductReference ProductPlacebo Product
Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions71.05 ± 29.82372.84 ± 26.92651.53 ± 28.403
Statistical analysis
  • Test Product vs Reference Product · Fieller's method · Equivalence ratio: 97.54 · 90% CI 94.6 to 104.7
PrimaryMean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions
Time frame:
Baseline to Day 84
Reported as:
Mean · percentage of lesion change
Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions
percentage of lesion changeTest ProductReference ProductPlacebo Product
Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions58.99 ± 30.03258.93 ± 29.04632.25 ± 41.322
Statistical analysis
  • Test Product vs Reference Product · Fieller's method · Equivalence ratio: 100.10 · 90% CI 96 to 109.3

Adverse events

Collected over 84 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product0/385 (0%)0/385 (0%)0/385 (0%)
Reference Product0/378 (0%)0/378 (0%)0/378 (0%)
Placebo Product0/127 (0%)0/127 (0%)0/127 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Test ProductReference ProductPlacebo ProductTotal
Mean20.1 ± 5.8320.3 ± 6.0718.9 ± 5.3420.0 ± 5.88
Sex: Female, Male
Sex: Female, Male(Participants)Test ProductReference ProductPlacebo ProductTotal
Female21621362491
Male16916565399
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test ProductReference ProductPlacebo ProductTotal
Hispanic or Latino23023074534
Not Hispanic or Latino15514853356
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test ProductReference ProductPlacebo ProductTotal
American Indian or Alaska Native0202
Asian199735
Native Hawaiian or Other Pacific Islander1124
Black or African American664415125
White22624375544
More than one race0000
Unknown or Not Reported737928180
08

Study locations

1 site
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2015, a primary completion of Apr 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 4 years 7 months after primary completion. A results delay was requested in Jun 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2015
First posted
Aug 4, 2015
Start
Jul 2015
Primary completionActual
Apr 2016
CompletionActual
Jun 2016
Results delay requested
Jun 27, 2016
Results first posted
Nov 16, 2020
Last update
Nov 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02515305
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Aug 4, 2015
Start date
Jul 2015
Primary completion
Apr 2016
Completion
Jun 2016
Results posted
Nov 16, 2020
Last update
Nov 8, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide

Start the discussion